Jeffrey Meckler Sells 8,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Key Points

• Director Jeffrey Meckler sold 8,000 shares at an average price of $45 under a pre‑arranged Rule 10b5‑1 plan, generating $360,000 and reducing his stake by 8.38% to 87,500 shares (≈$3.94M).
• Q1 results: Travere reported EPS of $0.05 (beating the ‑$0.24 consensus) and revenue of $127.2M, up 55.6% year‑over‑year but below estimates, while the company remains unprofitable with a negative net margin and ROE.
• Analyst and institutional interest: Several major analysts raised targets (e.g., TD Cowen to $60, Wells Fargo to $50) and large funds boosted positions, with the MarketBeat average target around $47.83 as the stock trades near $44.70.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Jeffrey Meckler sold 8,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director directly owned 87,500 shares of the company's stock, valued at $3,937,500. The trade was a 8.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Down 0.2%

Shares of Travere Therapeutics stock traded down $0.10 during trading hours on Wednesday, hitting $44.70. The company's stock had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $48.61. The business has a fifty day moving average of $32.59 and a 200 day moving average of $32.83. The company has a market capitalization of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.29. The company had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business's quarterly revenue was up 55.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) earnings per share. As a group, equities analysts forecast that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Travere Therapeutics by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company's stock valued at $158,059,000 after acquiring an additional 619,085 shares during the last quarter. State Street Corp boosted its stake in Travere Therapeutics by 47.8% during the 4th quarter. State Street Corp now owns 4,756,666 shares of the company's stock valued at $181,752,000 after acquiring an additional 1,538,827 shares during the last quarter. Perceptive Advisors LLC boosted its stake in Travere Therapeutics by 12.7% during the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company's stock valued at $163,469,000 after acquiring an additional 483,565 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Travere Therapeutics by 27.4% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company's stock valued at $41,203,000 after acquiring an additional 599,102 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Travere Therapeutics by 28.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company's stock valued at $85,849,000 after acquiring an additional 494,665 shares during the last quarter.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Analyst Ratings Changes

TVTX has been the subject of several analyst reports. Wall Street Zen downgraded shares of Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Weiss Ratings restated a "sell (e+)" rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Citigroup upped their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the company a "buy" rating in a research note on Tuesday. Wells Fargo & Company upped their target price on shares of Travere Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. decreased their target price on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a research note on Wednesday, March 25th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Travere Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $47.83.

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.